NCT07914907 GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection
| NCT ID | NCT07914907 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Condition | Rheumatoid Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-03-01 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability. Recent advances in generative artificial intelligence (GenAI), particularly large language models (LLMs), enable integration of heterogeneous clinical data and may improve clinical decision-making. However, there is limited real-world evidence (RWE) evaluating whether GenAI can meaningfully augment physician decision-making in routine care. This prospective, single-arm, nonrandomized interventional study evaluates the feasibility and impact of GenAI-assisted clinical decision support on physician assessment of rheumatoid arthritis bone erosion risk and disease-modifying antirheumatic drug selection in routine inpatient care. Treating physicians document their initial risk assessments and treatment decisions before reviewing patient-specific GenAI reports and subsequently record their assessments and decisions after reviewing the reports. The study evaluates changes in physician clinical decision-making within a learning health system framework. Final treatment decisions remain under the responsibility of the treating physicians. The study does not evaluate long-term patient clinical outcomes.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed RA patients meeting American College of Rheumatology / European League Against Rheumatism 2010 classification criteria * Consecutive inpatients admitted during study period Exclusion Criteria: * Patients subsequently determined not to have RA * Incomplete clinical data preventing risk or treatment assessment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07914907 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07914907 currently recruiting?
Yes, NCT07914907 is actively recruiting participants. Contact the research team at doctorjq@126.com for enrollment information.
Where is the NCT07914907 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07914907 clinical trial?
NCT07914907 is sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.